Quarterly Activities/Appendix 4C Cash Flow Report

• FY26 full-year revenue of US$90.2 million, exceeding guidance of US$87.0 million, representing 28% year-over-year growth.
• Accelerating Q4 global revenue growth, delivering US$27.0 million, +43% vs prior corresponding period (pcp).
• Received US Food and Drug Administration ('FDA') approval for CAP24 paddle lead, expanding the Evoke® System portfolio into surgical paddle lead procedures.

Saluda Medical, Inc. reported its Q4 FY26 activities and Appendix 4C Cash Flow Report. The company exceeded its FY26 revenue guidance with a full-year revenue of US$90.2 million, a 28% increase year-over-year. Q4 global revenue grew by 43% versus the prior corresponding period to US$27.0 million. The company also received FDA approval for its CAP24 paddle lead, expanding the Evoke System's portfolio into surgical paddle lead procedures. US sales force expansion met full-year targets, with an average of 89 fully trained sales representatives over FY26. The company will host an investor webinar on July 30, 2026, to discuss the results.

FY26 full-year revenue of US$90.2 million, exceeding guidance of US$87.0 million

Saluda Medical, Inc. remains focused on disciplined commercial execution, continued physician engagement and training, and expanding the benefits of objective, physiologic closed-loop neuromodulation to more patients.